Table 2.
Correlation analyses between age and expression levels of 17A, 51A, BACE1 and BC200 in plasma of Alzheimer disease (AD) patients and control (Ctrl) groups
| LEL | Age (Ctrl) | Age (AD) | Age (AD + Control) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| r2 | CI (95%) | P value | r2 | CI (95%) | P value | r2 | CI (95%) | P value | |
| 17A | 0.03 | −0.45~0.01 | 0.19 | 0.001 | −0.35~0.37 | 0.83 | 0.179 | −0.356~0.036 | 0.088 |
| 51A | 0.012 | −0.59~ − 0.10 | 0.01 | 0.02 | −0.18~0.44 | 0.31 | 0.175 | −0.360~0.017 | 0.095 |
| BACE1 | 0.02 | −0.35~0.32 | 0.30 | 0.005 | −0.24~0.44 | 0.65 | 0.217 | −0.394~ − 0.004 | 0.038 |
| BC200 | 0.08 | −0.55~0.02 | 0.04 | 0.04 | −0.07~0.48 | 0.11 | 0.116 | −0.313~0.085 | 0.271 |
LEL LncRNA expression level, AD Alzheimer disease, r spearman correlation coefficient, r2 coefficient of determination